**
A new weight loss medication, Foundayo, has received approval for use in the UK, marking a significant development in the public health landscape concerning obesity and type 2 diabetes management. This oral pill, developed by Eli Lilly, is the second GLP-1 receptor agonist to gain approval in the country, following the earlier introduction of Novo’s Wegovy. With an estimated 8.25 million individuals in the UK considering or currently using GLP-1 medications, Foundayo represents a new option in the fight against weight-related health issues.
Understanding Foundayo’s Mechanism
Foundayo, also known by its active ingredient orforglipron, functions as a GLP-1 receptor agonist. These drugs are designed to simulate the natural hormone responsible for regulating blood sugar levels, appetite, and digestion. In addition to its weight loss capabilities, Foundayo is also indicated for managing type 2 diabetes by helping to lower blood glucose levels.
Dr. Donald Grant, a general practitioner at The Independent Pharmacy, elaborates on the drug’s operation: “Foundayo mimics a hormone released naturally by the body post-meal, aiding in appetite control and digestion. When paired with a reduced-calorie diet and increased physical activity, it can support sustainable weight loss. For those with type 2 diabetes, it provides the added benefit of lowering elevated blood sugar levels.”
Accessibility and Pricing
Despite its approval, Foundayo will initially be available only through private prescriptions, as the NHS has not yet included it in its offerings. The Medicines and Healthcare products Regulatory Agency (MHRA) clarified that while the medication is sanctioned for usage, public access through the NHS remains unavailable at this time. Eli Lilly has indicated that the pill will be launched in the UK later this month, with a price point expected to be lower than that of Mounjaro, which currently retails at £330 for a monthly supply, although specific pricing details have yet to be confirmed.
Administration and Efficacy
One of Foundayo’s primary advantages over Wegovy is its ease of administration. It can be taken once daily without food or water restrictions, a contrast to Wegovy, which requires consumption on an empty stomach and mandates a waiting period before eating or taking other medications. Despite being designed for long-term use, Dr. Simon Cork from Anglia Ruskin University cautions that the weight loss outcomes associated with Foundayo may not be as pronounced as those from other treatments. Nevertheless, he maintains that patients can still expect “significant, clinically meaningful changes to their weight.”
Potential Side Effects
As with any medication, Foundayo comes with a range of potential side effects. Common adverse reactions include nausea, diarrhoea, and abdominal cramps, while other reported symptoms can encompass fatigue, headaches, and vision problems. The National Institute for Health and Care Excellence (NICE) has provided guidance that outlines these risks, underscoring the importance of monitoring patient reactions throughout the treatment process.
Why it Matters
The introduction of Foundayo into the UK market could have far-reaching implications for public health, particularly in addressing the obesity epidemic and its associated health complications, such as type 2 diabetes. With millions of individuals struggling with weight management, this new option not only diversifies the available treatments but also offers hope to those who may have previously found limited success with existing therapies. As healthcare systems seek effective solutions for chronic conditions, the arrival of Foundayo signals a potentially transformative shift in how obesity and diabetes are managed, prompting a need for ongoing evaluation of its long-term effectiveness and safety.
